Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Context Therapeutics Inc. - Common Stock
(NQ:
CNTX
)
0.2758
-0.0292 (-9.57%)
Delayed Quote
Updated: 12:36 PM EDT, Oct 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Context Therapeutics Inc. - Common Stock
< Previous
1
2
3
Next >
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
September 09, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
August 05, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
July 06, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
June 15, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 09, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
May 27, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
May 18, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
May 06, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
April 02, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
March 23, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
March 19, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics to Participate in Upcoming Investor Conferences
February 09, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From
Context Therapeutics Inc.
Via
GlobeNewswire
Kartoon Studios (NYSE: TOON) Expansion Fuels 2026-2027 Upside – DVLT, UFG, VRME, ARBE More Inside
January 05, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
December 16, 2025
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
November 07, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
November 05, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics to Participate in Upcoming Investor Conferences
October 28, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
October 06, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics to Participate in Upcoming Investor Conferences
August 27, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
August 06, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
June 02, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
May 29, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
May 07, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Chief Medical Officer Transition
May 05, 2025
Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
April 30, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
April 09, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
